InterMune Takes Off
Updated from Oct. 16
Shares of InterMune (ITMN) vaulted Tuesday after the company scored an exclusive collaboration agreement with Swiss giant Roche for hepatitis C drugs.
The companies said after the bell Monday that they plan to develop and commercialize products from InterMune's HCV protease inhibitor program. The Brisbane, Calif., biotech said it will get a $60 million upfront payment and up to $470 million in milestones, including $35 million in the next year.
InterMune shares recently were up $4.40, or 26%, to $21.23, on volume of more than 2.5 million shares. Average daily volume is just 313,000 shares.The agreement includes InterMune's lead candidate compound ITMN-191, which is expected to enter clinical trials before the end of the year. The companies also will collaborate on a research program to identify, develop and commercialize novel second-generation HCV protease inhibitors. For ITMN-191, Roche will fund 67% of the global development costs, and the companies will co-commercialize the product in the U.S. and share profits on a 50-50 basis. InterMune will receive royalties outside the U.S. InterMune may opt out of either co-development or co-commercialization for ITMN-191, in which case InterMune would receive higher royalties on ex-U.S. sales, and royalties instead of profit-sharing in the U.S. "This agreement with InterMune is part of our ongoing commitment to advancing therapies for hepatitis C patients," said Peter Hug, global head of pharma partnering for Roche. "We believe that protease inhibitors may become an important new component of HCV treatments and we look forward to working with InterMune in the development of ITMN-191 and other potential compounds that may emerge from our collaboration." Dan Welch, InterMune's CEO, said, "We are very pleased to be partnering with Roche. We believe this partnership will help accelerate the development of ITMN-191 and future second-generation protease inhibitors, while allowing InterMune to share in the substantial value creation opportunity of this important program."
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV